Compare PHGE & MLEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHGE | MLEC |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | Israel | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.1M |
| IPO Year | N/A | N/A |
| Metric | PHGE | MLEC |
|---|---|---|
| Price | $2.44 | $0.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $26.00 | N/A |
| AVG Volume (30 Days) | 118.2K | ★ 128.9K |
| Earning Date | 11-12-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.42 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 170.36 |
| 52 Week Low | $2.31 | $0.39 |
| 52 Week High | $22.06 | $8.00 |
| Indicator | PHGE | MLEC |
|---|---|---|
| Relative Strength Index (RSI) | 49.70 | 35.75 |
| Support Level | $4.10 | $0.42 |
| Resistance Level | $6.03 | $0.50 |
| Average True Range (ATR) | 0.52 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 36.73 | 27.41 |
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.